I Reunión Post-European Headache Federation: revisión de las novedades presentadas en el Congreso de la European Headache Federation de 2020

2021 ◽  
Vol 72 (S02) ◽  
pp. S1
Author(s):  
José Miguel Láinez Andrés ◽  
Messoud Ashina ◽  
Robert Belvís Nieto ◽  
Samuel Díaz Insa ◽  
David Ezpeleta Echávarri ◽  
...  
Keyword(s):  
European Headache Federation

scholarly journals Diagnosis and management of migraine in ten steps

2021 ◽  
Author(s):  
Anna K. Eigenbrodt ◽  
Håkan Ashina ◽  
Sabrina Khan ◽  
Hans-Christoph Diener ◽  
Dimos D. Mitsikostas ◽  
...  
Keyword(s):  
Clinical Decision Making ◽  
Consensus Statement ◽  
Preventive Treatment ◽  
Primary Headache ◽  
Headache Disorder ◽  
Clinical Decision ◽  
Diagnosis And Management ◽  
Primary Headache Disorder ◽  
Management Of Complications ◽  
European Headache Federation

AbstractMigraine is a disabling primary headache disorder that directly affects more than one billion people worldwide. Despite its widespread prevalence, migraine remains under-diagnosed and under-treated. To support clinical decision-making, we convened a European panel of experts to develop a ten-step approach to the diagnosis and management of migraine. Each step was established by expert consensus and supported by a review of current literature, and the Consensus Statement is endorsed by the European Headache Federation and the European Academy of Neurology. In this Consensus Statement, we introduce typical clinical features, diagnostic criteria and differential diagnoses of migraine. We then emphasize the value of patient centricity and patient education to ensure treatment adherence and satisfaction with care provision. Further, we outline best practices for acute and preventive treatment of migraine in various patient populations, including adults, children and adolescents, pregnant and breastfeeding women, and older people. In addition, we provide recommendations for evaluating treatment response and managing treatment failure. Lastly, we discuss the management of complications and comorbidities as well as the importance of planning long-term follow-up.

scholarly journals Framing education on headache disorders into the Global Burden of Disease Study 2010. The European Headache Federation stands ready

2013 ◽  
Vol 14 (1) ◽  
Author(s):  
Paolo Martelletti ◽  
Dimos-Dimitrios Mitsikostas ◽  
Christian Lampl ◽  
Zaza Katsarava ◽  
Vera Osipova ◽  
...  
Keyword(s):  
Burden Of Disease ◽  
Global Burden Of Disease ◽  
Global Burden ◽  
Headache Disorders ◽  
European Headache Federation ◽  
Disease Study

scholarly journals Refractory Headache: One Term does Not cover All – A Statement of the European Headache Federation

2014 ◽  
Vol 15 (1) ◽  
Author(s):  
Christian Lampl ◽  
Rigmor Jensen ◽  
Paolo Martelletti ◽  
Dimos-Dimitrios Mitsikostas
Keyword(s):  
Refractory Headache ◽  
European Headache Federation

scholarly journals Gleaning after the European Headache Federation consensus statement on refractory chronic migraine

2014 ◽  
Vol 15 (1) ◽  
Author(s):  
Paolo Martelletti ◽  
Christian Lampl ◽  
Michael-Bjorn Russell ◽  
Dimos-Dimitrios Mitsikostas
Keyword(s):  
Chronic Migraine ◽  
Consensus Statement ◽  
Refractory Chronic Migraine ◽  
European Headache Federation

scholarly journals Additive Interaction Between Onabotulinumtoxin-A and Erenumab in Patients With Refractory Migraine

2021 ◽  
Vol 12 ◽  
Author(s):  
Marcello Silvestro ◽  
Alessandro Tessitore ◽  
Fabrizio Scotto di Clemente ◽  
Giorgia Battista ◽  
Gioacchino Tedeschi ◽  
...  
Keyword(s):  
Chronic Migraine ◽  
Therapeutic Strategy ◽  
Combined Therapy ◽  
Case Series ◽  
Additive Interaction ◽  
C Fibers ◽  
Onabotulinumtoxin A ◽  
Effective Therapeutic Strategy ◽  
Refractory Migraine ◽  
European Headache Federation

In the last decade, notable progresses have been observed in chronic migraine preventive treatments. According to the European Headache Federation and national provisions, onabotulinumtoxin-A (BTX-A) and monoclonal antibodies acting on the pathway of calcitonin gene–related peptide (CGRP-mAbs) should not be administered in combination due to supposed superimposable mechanism of action and high costs. On the other hand, preclinical observations demonstrated that these therapeutic classes, although operating directly or indirectly on the CGRP pathway, act on different fibers. Specifically, the CGRP-mAbs prevent the activation of the Aδ-fibers, whereas BTX-A acts on C-fibers. Therefore, it can be argued that a combined therapy may provide an additive or synergistic effect on the trigeminal nociceptive pathway. In the present study, we report a case series of 10 patients with chronic migraine who experienced significant benefits with the combination of both erenumab and BTX-A compared to each therapeutic strategy alone. A reduction in frequency and intensity of headache attacks (although not statistically significant probably due to the low sample size) was observed in migraine patients treated with a combined therapy with BTX-A and erenumab compared to both BTX-A and erenumab alone. Moreover, the combined therapy with BTX-A and erenumab resulted in a statistically significant reduction in the symptomatic drug intake and in migraine-related disability probably related to a reduced necessity or also to a better responsiveness to rescue treatments. Present data suggest a remodulation of current provisions depriving patients of an effective therapeutic strategy in peculiar migraine endophenotypes.

Sign in / Sign up

Export Citation Format

Share Document